Live price temporarily unavailable.
Caribou Biosciences (CRBU) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $5.79M | $12.4M | $9.60M | $13.9M | $34.5M | $9.99M | $11.2M |
| Growth (year over year) | — | +113.6% | −22.4% | +44.3% | +148.9% | −71.0% | +11.7% |
| Operating income | −$34.3M | −$36.1M | −$67.0M | −$106.4M | −$116.1M | −$166.6M | −$148.3M |
| Operating margin | −592.7% | −292.2% | −697.8% | −768.2% | −336.6% | −1667.2% | −1329.4% |
| Net income | −$23.4M | −$34.3M | −$66.9M | −$99.4M | −$102.1M | −$149.1M | −$148.1M |
| Net margin | −404.8% | −277.6% | −697.3% | −717.8% | −296.1% | −1491.9% | −1327.4% |
| EPS (diluted) | −$2.80 | −$4.01 | −$2.11 | −$1.64 | −$1.38 | −$1.65 | −$1.59 |
| Balance sheet | |||||||
| Cash and equivalents | $41.1M | $16.0M | $240.4M | $58.3M | $51.2M | $16.3M | $12.4M |
| Total assets | — | $36.0M | $442.4M | $373.8M | $432.2M | $313.3M | $175.4M |
| Total liabilities | — | $18.2M | $54.5M | $72.9M | $63.8M | $60.4M | $53.2M |
| Shareholders' equity | $7.46M | −$23.4M | $387.8M | $300.9M | $368.4M | $253.0M | $122.2M |
| Cash flow | |||||||
| Operating cash flow | −$32.0M | −$33.2M | −$32.5M | −$91.0M | −$93.3M | −$138.2M | −$111.0M |
| Capital expenditure | $884.0K | $317.0K | $2.12M | $6.45M | $11.6M | $4.88M | $1.36M |
| Free cash flow | −$32.9M | −$33.5M | −$34.6M | −$97.4M | −$104.9M | −$143.1M | −$112.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.02M | $2.08M | $2.35M | $2.67M | $2.20M | $3.94M | $2.40M | $1.50M |
| Growth (year over year) | −91.4% | −41.6% | −3.1% | −23.0% | +8.6% | +89.7% | +1.9% | −43.8% |
| Operating income | −$38.2M | −$38.9M | −$42.9M | −$47.6M | −$29.4M | −$28.5M | −$26.3M | −$25.3M |
| Operating margin | −1889.2% | −1871.7% | −1823.8% | −1784.0% | −1337.6% | −722.0% | −1096.4% | −1690.4% |
| Net income | −$34.7M | −$35.5M | −$40.0M | −$54.1M | −$27.5M | −$26.5M | −$25.1M | −$24.3M |
| Net margin | −1713.6% | −1708.7% | −1699.6% | −2028.4% | −1253.3% | −672.1% | −1046.5% | −1619.9% |
| EPS (diluted) | −$0.38 | −$0.39 | −$0.43 | −$0.58 | −$0.30 | −$0.28 | −$0.26 | −$0.24 |
| Balance sheet | ||||||||
| Cash and equivalents | $32.0M | $16.3M | $29.4M | $25.2M | $11.1M | $12.4M | $12.1M | $26.2M |
| Total assets | $344.3M | $313.3M | $273.7M | $220.9M | $195.0M | $175.4M | $149.0M | $142.8M |
| Total liabilities | $63.1M | $60.4M | $56.4M | $54.8M | $53.1M | $53.2M | $47.0M | $44.7M |
| Shareholders' equity | $281.2M | $253.0M | $217.2M | $166.1M | $141.8M | $122.2M | $102.0M | $98.1M |
| Cash flow | ||||||||
| Operating cash flow | −$32.7M | −$35.5M | −$36.7M | −$28.3M | −$25.2M | −$20.8M | −$27.0M | −$22.8M |
| Capital expenditure | $673.0K | $518.0K | $1.04M | $418.0K | $115.0K | −$216.0K | $72.0K | $1.00K |
| Free cash flow | −$33.3M | −$36.0M | −$37.8M | −$28.7M | −$25.3M | −$20.6M | −$27.1M | −$22.8M |
From Caribou Biosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Rachel Elizabeth Haurwitz is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
Source: Wikipedia — Rachel Haurwitz
No recent news mentioning Caribou Biosciences in our feed yet.